{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360004239216359296.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.3109/14397595.2013.843757"}},{"identifier":{"@type":"URI","@value":"http://www.tandfonline.com/doi/pdf/10.3109/14397595.2013.843757"}},{"identifier":{"@type":"PMID","@value":"24252045"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors"}],"description":[{"notation":[{"@value":"To examine the effectiveness of tocilizumab (TCZ) in preventing joint destruction in patients with inadequate response to tumor necrosis factor inhibitors (TNF-IR) by assessing X-rays.RA patients were extracted from the Retrospective actemra investigation for optimal needs of RA patients (REACTION) study. Parameters and components of disease activity were evaluated during anti-TNF treatment and during TCZ treatment. X-ray images of hands and feet at the beginning of this study during anti-TNF treatment (Pre), at the start point of TCZ treatment (Baseline) and after TCZ treatment (Post) were collected for assessing joint destruction.Forty-five patients from the REACTION study fulfilled the criteria of clinical TNF-IR. During anti-TNF treatment, mean DAS28-ESR rose from 5.35 to 5.87 (mean observation duration, 16 months) but improved significantly to 2.94 (P0.0001) at 52 weeks after switching to TCZ. Mean change in van der Heijde-modified Sharp score (TSS) during anti-TNF treatment was 3.17 in this TNF-IR population. After switching to TCZ, mean change in TSS was 1.20 (P0.05). Rate of radiographic non-progression improved to 66.7% during TCZ treatment from 40.0% during anti-TNF treatment. The predictive factor for no radiographic progression after switching to TCZ was a HAQ disability index (HAQ-DI) score of ≤ 1.88 at switching to TCZ.TCZ was a good treatment option for improving signs and symptoms and inhibiting progression of joint damage in patients with clinical and structural TNF-IR."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380004239216359299","@type":"Researcher","foaf:name":[{"@value":"Yoshiya Tanaka"}]},{"@id":"https://cir.nii.ac.jp/crid/1030003658330673152","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"50179610"},{"@type":"NRID","@value":"1000050179610"},{"@type":"NRID","@value":"9000000877887"},{"@type":"NRID","@value":"9000014207889"},{"@type":"NRID","@value":"9000016383446"},{"@type":"NRID","@value":"9000001489795"},{"@type":"NRID","@value":"9000322108971"},{"@type":"NRID","@value":"9000021351486"},{"@type":"NRID","@value":"9000398138928"},{"@type":"NRID","@value":"9000001333374"},{"@type":"NRID","@value":"9000379605985"},{"@type":"NRID","@value":"9000340953057"},{"@type":"NRID","@value":"9000259336870"},{"@type":"NRID","@value":"9000413476545"},{"@type":"NRID","@value":"9000340953021"},{"@type":"NRID","@value":"9000017036355"},{"@type":"NRID","@value":"9000323291007"},{"@type":"NRID","@value":"9000021357712"},{"@type":"NRID","@value":"9000375922338"},{"@type":"NRID","@value":"9000325829809"},{"@type":"NRID","@value":"9000290133212"},{"@type":"NRID","@value":"9000258205043"},{"@type":"NRID","@value":"9000240536408"},{"@type":"NRID","@value":"9000412228840"},{"@type":"NRID","@value":"9000298898221"},{"@type":"NRID","@value":"9000000669795"},{"@type":"NRID","@value":"9000259336893"},{"@type":"NRID","@value":"9000022105317"},{"@type":"NRID","@value":"9000408630841"},{"@type":"NRID","@value":"9000000381633"},{"@type":"NRID","@value":"9000340953187"},{"@type":"NRID","@value":"9000340953079"},{"@type":"NRID","@value":"9000340953032"},{"@type":"NRID","@value":"9000022122608"},{"@type":"NRID","@value":"9000000736177"},{"@type":"NRID","@value":"9000001758253"},{"@type":"NRID","@value":"9000340953159"},{"@type":"NRID","@value":"9000021888840"},{"@type":"NRID","@value":"9000345290454"},{"@type":"NRID","@value":"9000283415068"},{"@type":"NRID","@value":"9000314791566"},{"@type":"NRID","@value":"9000329896112"},{"@type":"NRID","@value":"9000340953044"},{"@type":"NRID","@value":"9000018782441"},{"@type":"NRID","@value":"9000340953195"},{"@type":"NRID","@value":"9000340953203"},{"@type":"NRID","@value":"9000021930965"},{"@type":"NRID","@value":"9000365496796"},{"@type":"NRID","@value":"9000107381121"},{"@type":"NRID","@value":"9000413480342"},{"@type":"NRID","@value":"9000380481812"},{"@type":"NRID","@value":"9000262367176"},{"@type":"NRID","@value":"9000259337073"},{"@type":"NRID","@value":"9000265566113"},{"@type":"NRID","@value":"9000368418366"},{"@type":"NRID","@value":"9000261023324"},{"@type":"NRID","@value":"9000326644699"},{"@type":"NRID","@value":"9000240536366"},{"@type":"NRID","@value":"9000340952994"},{"@type":"NRID","@value":"9000398139320"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/read0023699"}],"foaf:name":[{"@value":"Tsutomu Takeuchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239216359170","@type":"Researcher","foaf:name":[{"@value":"Koichi Amano"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239216359302","@type":"Researcher","foaf:name":[{"@value":"Kazuyoshi Saito"}]},{"@id":"https://cir.nii.ac.jp/crid/1420001326221745280","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"50441853"},{"@type":"NRID","@value":"1000050441853"},{"@type":"NRID","@value":"9000017386744"},{"@type":"NRID","@value":"9000386384846"},{"@type":"NRID","@value":"9000391771937"},{"@type":"NRID","@value":"9000391776330"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/8733"}],"foaf:name":[{"@value":"Kentaro Hanami"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239216359432","@type":"Researcher","foaf:name":[{"@value":"Masao Nawata"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239216359429","@type":"Researcher","foaf:name":[{"@value":"Shunsuke Fukuyo"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239216359304","@type":"Researcher","foaf:name":[{"@value":"Hideto Kameda"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239216359427","@type":"Researcher","foaf:name":[{"@value":"Yuko Kaneko"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239216359424","@type":"Researcher","foaf:name":[{"@value":"Takahiko Kurasawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239216359298","@type":"Researcher","foaf:name":[{"@value":"Hayato Nagasawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239216359176","@type":"Researcher","foaf:name":[{"@value":"Daisuke Hoshi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239216359172","@type":"Researcher","foaf:name":[{"@value":"Eri Sato"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004239216359175","@type":"Researcher","foaf:name":[{"@value":"Hisashi Yamanaka"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"14397595"},{"@type":"EISSN","@value":"14397609"}],"prism:publicationName":[{"@value":"Modern Rheumatology"}],"dc:publisher":[{"@value":"Oxford University Press (OUP)"}],"prism:publicationDate":"2013-11-05","prism:volume":"24","prism:number":"3","prism:startingPage":"399","prism:endingPage":"404"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","url":[{"@id":"http://www.tandfonline.com/doi/pdf/10.3109/14397595.2013.843757"}],"createdAt":"2013-11-05","modifiedAt":"2022-01-19","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Adult","dc:title":"Adult"},{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Tumor%20Necrosis%20Factor-alpha","dc:title":"Tumor Necrosis Factor-alpha"},{"@id":"https://cir.nii.ac.jp/all?q=Middle%20Aged","dc:title":"Middle Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Antibodies,%20Monoclonal,%20Humanized","dc:title":"Antibodies, Monoclonal, Humanized"},{"@id":"https://cir.nii.ac.jp/all?q=Receptors,%20Interleukin-6","dc:title":"Receptors, Interleukin-6"},{"@id":"https://cir.nii.ac.jp/all?q=Severity%20of%20Illness%20Index","dc:title":"Severity of Illness Index"},{"@id":"https://cir.nii.ac.jp/all?q=Arthritis,%20Rheumatoid","dc:title":"Arthritis, Rheumatoid"},{"@id":"https://cir.nii.ac.jp/all?q=Treatment%20Outcome","dc:title":"Treatment Outcome"},{"@id":"https://cir.nii.ac.jp/all?q=Antirheumatic%20Agents","dc:title":"Antirheumatic Agents"},{"@id":"https://cir.nii.ac.jp/all?q=Retreatment","dc:title":"Retreatment"},{"@id":"https://cir.nii.ac.jp/all?q=Disease%20Progression","dc:title":"Disease Progression"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Joints","dc:title":"Joints"},{"@id":"https://cir.nii.ac.jp/all?q=Aged","dc:title":"Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Retrospective%20Studies","dc:title":"Retrospective Studies"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040282257295498240","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"26860764"},{"@type":"JGN","@value":"JP26860764"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-26860764/"}],"notation":[{"@language":"ja","@value":"神経伝達物質が骨リモデリングに与える影響に関する研究"},{"@language":"en","@value":"Dopamine receptor signaling regulates human osteoclastogenesis."}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050025031481564928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360001114033913088","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002217661110272","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011143850707968","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011146598919552","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate"}]},{"@id":"https://cir.nii.ac.jp/crid/1360282589010597504","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620879403648","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360306904417025920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST registry"}]},{"@id":"https://cir.nii.ac.jp/crid/1360564064179607808","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095964455040","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855568530121856","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569011412224","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569328636416","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995941744384","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469683053440","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943696288512","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944890866048","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418876950528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544421023681536","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370153820800","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320710326528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793415230592","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795248011520","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Stanford health assessment questionnaire: dimensions and practical applications"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233271146705920","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.3109/14397595.2013.843757"},{"@type":"KAKEN","@value":"PRODUCT-15304343"},{"@type":"OPENAIRE","@value":"doi_dedup___::02af1e42cbbcb8ae69d201dbe16c4166"},{"@type":"CROSSREF","@value":"10.1093/rheumatology/keae334_references_DOI_K66p2XdytgXONQJEqv92lv16gam"}]}